Physician profile
James Eric Stanford
NPI 1447565775
$3,265.39
in general payments reported to CMS, 2019-2025
13 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $22.68 · 2021: $208 · 2022: $1,317 · 2023: $388 · 2024: $902 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $792 · Food and Beverage: $658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $792.16 |
| Food and Beverage | $657.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prime Surgical, LLC | $2,250.04 | 2019-2025 | |
| Arthrex, INC. | $326.33 | 2021-2024 | |
| Kerecis Limited | $155.15 | 2023-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Ferring Pharmaceuticals INC. | $143.42 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $83.43 | 2022 | |
| Depuy Synthes Sales INC. | $82.64 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $76.70 | 2023-2025 | Exparel, Zilretta, Iovera |
| Sanofi-Aventis U.S. LLC | $59.69 | 2023 | |
| Smith+Nephew, INC. | $22.68 | 2020 | |
| Olympus America INC. | $19.23 | 2019 | |
| Trice Medical, INC. | $16.49 | 2023 | |
| Medical Device Business Services, INC. | $15.09 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Stanford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.